Extraordinary General Meeting of InDex Pharmaceuticals Holding AB (publ) took place on January 12, 2021 in Setterwalls Advokatbyraer's premises at Sturegatan 10, Stockholm.

Attendance at the meeting took place exclusively by postal ballot. At the meeting, the following decisions were made.

Resolution on amendment of the Articles of Association The Annual General Meeting resolved, in accordance with the Board's proposal, on amendments to the Company's Articles of Association regarding, among other things, the conditions for participation in the Annual General Meeting, the limits for share capital and the number of shares.

The Annual General Meeting made a total of two separate resolutions amending the Articles of Association, one of which is conditional on the Board, with the support of the authorization from the Annual General Meeting, deciding on the issue of shares, resulting in the number of shares and share capital exceeding the Articles of Association. the Annual General Meeting on January 12, 2021 and is not conditional on the Board deciding on the issue of shares) limits.

Resolution to authorize the Board of Directors to issue shares with preferential rights for the shareholders

In accordance with the Board's proposal, the Annual General Meeting resolved to authorize the Board to, for the period until the next Annual General Meeting, decide to increase the company's share capital. Issuance must be possible against cash payment and / or with a provision for non-cash or set-off or other conditions.

By decision based on the authorization, it must be possible to issue a maximum of as many shares in total as can be done without changing the articles of association adopted at any given time. The purpose of the authorization is to make it possible to raise capital in an efficient manner to enable further development of the company's operations.

Contact:

Peter Zerhouni

Tel: +46 (0) 8 122 038 50

Email: peter.zerhouni@indexpharma.com

Briefly about InDex Pharmaceuticals Holding AB (publ)

InDex is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The company's main asset is the drug candidate cobitolimod, which is in the late clinical development phase for the treatment of moderate to severe ulcerative colitis - a functional impairment, chronic inflammation of the colon. InDex has also developed a platform of patent-protected substances, so-called DNA-based Immunomodulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases.

InDex is based in Stockholm. The company's shares (short name INDEX) are traded on the Nasdaq First North Growth Market. Redeye AB with e-mail address certifiedadviser@redeye.se and telephone number +46 8 121 576 90 is the Company's Certified Adviser.

(C) 2021 Electronic News Publishing, source ENP Newswire